| |
Caraco Pharmaceutical
Laboratories, Ltd. continues to focus on providing quality products to the
pharmaceutical marketplace and ultimately the end user, the consumer
patient. We manufacture oral dosage products across various therapeutic
categories, which will be augmented with other dosage forms in the future.
As we continue to develop our product portfolio, we must strive to reinforce
our commitment to quality, limit our internal costs and increase our
manufacturing efficiencies. In the global generic pharmaceutical
environment, Caraco is well positioned or “Built to Fit.” The management
hierarchy is built for efficiencies in managing our growth and equally built
for managing to maintain control of our costs. |
| |
|
| |
Our company has a dedicated team
of individuals that bring with them a host of talents and assets. This
capable team collectively drives the success of our company both tactically
and strategically. We are very optimistic of our capability to support our
growth and have high expectations for the years ahead.
|
| |
|
| |
The direct relationship with Sun
Pharma, our majority shareholder, allows Caraco “economies in scale” with
access to a vast adroit development team that is typically not available to
a company our size. Combine this with our streamlined company, the ability
to move deftly and adjust to day-to-day change necessary in a rapidly
growing company, such as ours, and you find that Caraco is uniquely
positioned in the US marketplace. Our core management team has a strong
attention to detail with a commitment to customer satisfaction, which is
displayed in the pride we take in our customer care. We are building our
future by focusing on succession planning which only strengthens our
long-term commitment to excellence and service to our customers. It is a
rare combination that only augments our execution. |
| |
The generic pharmaceutical industry is highly
competitive. We must continually work to eliminate costs that could
negatively impact our production while providing additional focus on
quality. We need to be custodians of the industry by educating the public at
every turn as to the value that generic pharmaceuticals offer in reducing
healthcare costs in the US, and how Caraco is part that solution. |
| |
|
| |
Future development and growth of
our company will be fueled by various sources. Where synergistic, Caraco
will continue to work on development opportunities with Sun Pharma into the
foreseeable future. Simultaneously, we will pursue other avenues of
development including but not limited to our own internal development,
working with development partners or third party formulators, in-licensing
of authorized generics and acquisitions of ANDAs that may or may not be
currently marketed by other pharmaceutical companies. |
| |
|
| |
Further we will build our team
of personnel by attracting qualified individuals available from the industry
in order to compliment and support the talented team of people we have
working at Caraco today; people that want to be part of a global solution. |
| |
|
| |
In the last ten years the
generic industry has evolved from domestic research and development teams to
what is now a more global effort. Our development is consistent with this
evolution. This has allowed us to reduce or eliminate costs in developing
our product portfolio while improving output. This is our fiduciary role and
allows us an opportunity to do our part in curbing healthcare costs in the
US while maximizing the return on investment for our shareholders. Caraco is
part of a global pharmaceutical solution. From the cost effective research
and development of raw material, to the finished, quality product that
reaches the pharmacies across the nation. |
| |
Regards |
| |
- Daniel H. Movens |
| |
|
